...veteran of the global BD team of Merck & Co. Inc....

...By Paul Bonanos, Associate Editor Merck’s roster of COVID-19 countermeasures gained via deals continued to shrink...
...HHS and the Department of Defense.A Merck spokesperson declined to tell BioCentury how much money Merck...
...patients following stem cell transplantation. Merck’s spokesperson said that trial is unaffected by Thursday’s decision.Since Merck’s...

...statement published Wednesday in The New York Times that Kenneth Frazier, chairman and CEO of Merck & Co. Inc....

...study, INDUCE-4, was evaluating feladilimab vs. placebo in combination with pembrolizumab and chemotherapy. GSK is partnered with Merck & Co. Inc....

...veteran of the global BD team of Merck & Co. Inc....

...as partner. Jurgeit was a partner at Lundbeckfonden Emerge and previously served as director at Merck...

...among the three potential targets.The new deal comes about four months after Artios partnered with Merck...

...human T cell ALL lines, the compound reduced proliferation and synergized with PARP inhibitor Lynparza olaparib.Merck & Co. Inc....

...as CEO-partner and became CEO of portfolio company Generate Biomedicines Inc. Nally, an 18-year veteran of Merck & Co. Inc....

...at the Merck Research Laboratories unit of Merck & Co. Inc....